Hormonal
48 weeks of tirzepatide treatment significantly improves liver steatosis, liver enzymes, and surrogate markers of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).
For patients with both fatty liver disease and type 2 diabetes, tirzepatide is a well-tolerated treatment that significantly reduces liver fat, improves liver enzyme levels, and slows down fibrosis markers over 48 weeks. While gastrointestinal side effects like nausea are common, they are typically mild and do not force most patients to stop the medication. The benefits extend beyond just weight loss, likely due to the specific dual-action mechanism of the drug on liver metabolism.
Tirzepatide treatment for T2DM in patients with MASLD significantly improved liver steatosis and injury, surrogate markers of liver fibrosis, and diabetes status, and reduced body weight.
Why this rating
Single-arm, open-label, prospective observational pilot study with a small sample size (n=13 completers), lacking a control group.
Source
Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus
Taeang Arai et al. · Hepatology Research · 2025
DOI 10.1111/hepr.14241
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →